|Day Low/High||91.51 / 94.56|
|52 Wk Low/High||70.89 / 92.87|
For now, any rebound is a short-term trading opportunity and nothing more.
Rather than try to catch falling knives, traders should give a look at Merck, IBM and Procter & Gamble.
The VanEck Morningstar Wide Moat ETF has held its own against the SPDR S&P 500 ETF and diversified giant Berkshire Hathaway.
There will have to be an adjustment made to their Covid vaccine and others at some point.
Let's check the charts of three drug names, Merck, Eli Lilly and Bristol-Myers Squibb.
Upside - +74% (enters strategic agreement with Immune Therapeutics for rights to low dose naltrexone) - +18% (earnings, guidance) - +16% (earnings, guidance) - +14% (earnings) - +11% (earnings, guidance) - +10% (earnings, guidance) - +9.1% (highligh...
Wednesday's session was dominated by traders, algorithmic traders for sure, but traders nonetheless. The PMs mostly sat on their hands.
Here's where I think MRK can go and how to play it.
After receiving an FDA approval, the small-cap biotech looks well positioned as a covered call candidate.
Recently poor sector performance is creating opportunity for long-term investors.
It's always surprising how quickly stocks can reverse for no real reason.
A closer look at the fund's composition leads to a few head-scratchers, but most of the names seem to fairly represent its focus.
Just a week ago Jerome Powell referred to the labor market as 'strong.' Now, economists, traders, investors, and the public are just not quite sure what to expect Friday.
Probably not, but there are some positives there that will help in the search for a bottom.
Negative returns for 2022? It's a midterm election year. We will see increased volatility. Anything is possible, and it would not surprise me.
Friday might be a market holiday, but it became obvious on Wednesday that trading volumes had started to truly dwindle.
Perhaps the rally had been set up by the depth of the pressure placed on financial markets over the prior three days. Perhaps.
Here we'll look at the iShares Genomics Immunology and Healthcare ETF and the Cancer Immunotherapy ETF to see how they stack up.
Looking at the top five in the DJIA: * American Express breaches its 20-day moving average ($174.93) * Salesforce back to the mid-$260s after a big spill * Intel is gapping above its 50-day moving average ($51.13) after the announcement of its plan ...
Sector selection will remain paramount as pandemic effects continue to permeate.
J&J will be separating into two distinct firms, but not right away.
I continue to get good feedback with regard to FibroGen. The above is part of a publication on myelodysplastic syndrome. I would note that Acceleron is being acquired by Merck for $11 billion. Acceleron has a drug on market which treats 15%-20% ...
The two big names disappointed after hours Thursday, but one is more of a concern than the other.
We had almost forgotten that sometimes Mr. Market can still land a ham-sized fist squarely upon that beaming smile of yours.
The lack of urgency at the FDA, as it is in the defense space, is alarming.
A recent trio of acquisition deals indicates the doldrums in the sector may be over.